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Mitochondria are dynamic subcellular organelles that
convert nutrient intermediates into readily available
energy equivalents. Optimal mitochondrial function is
ensured by a highly evolved quality control system,
coordinated by protein machinery that regulates a process
of continual fusion and fission. In this work, we provide
in vivo evidence that the ATP-independent metallopro-
tease OMA1 plays an essential role in the proteolytic
inactivation of the dynamin-related GTPase OPA1 (optic
atrophy 1). We also show that OMA1 deficiency causes a
profound perturbation of the mitochondrial fusion–fission
equilibrium that has important implications for metabolic
homeostasis. Thus, ablation of OMA1 in mice results in
marked transcriptional changes in genes of lipid and
glucose metabolic pathways and substantial alterations
in circulating blood parameters. Additionally, Oma1-
mutant mice exhibit an increase in body weight due to
increased adipose mass, hepatic steatosis, decreased en-
ergy expenditure and impaired thermogenenesis. These
alterations are especially significant under metabolic
stress conditions, indicating that an intact OMA1-OPA1
system is essential for developing the appropriate adaptive
response to different metabolic stressors such as a high-fat
diet or cold-shock. This study provides the first description
of an unexpected role in energy metabolism for the
metalloprotease OMA1 and reinforces the importance of
mitochondrial quality control for normal metabolic function.
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Introduction
Mitochondria are fundamental and highly dynamic orga-
nelles of eukaryotic cells that play critical roles in energy
generation, control of intermediate metabolism, homeostasis
of intracellular calcium and regulation of apoptosis events
(Mammucari and Rizzuto, 2010; Wallace et al, 2010).
Additionally, mitochondria are also the primary source of
endogenous reactive oxygen species (Orrenius et al, 2007).
Due to these multiple functions, it is not surprising that
mitochondrial alterations have been associated with many
pathological conditions including cancer, neurodegenerative
disorders and cardiovascular diseases (Green and Kroemer,
2004; Wallace, 2005; Chen and Chan, 2009; Fulda et al, 2010).
To maintain their functional activities, mitochondria have
developed a quality control mechanism, in which several
proteolytic enzymes play important roles (Tatsuta and
Langer, 2008). These mitochondrial proteases, together with
some mitochondrial chaperones, monitor the folding and
assembly of mitochondrial proteins and selectively degrade
misfolded and non-assembled polypeptides from the orga-
nelle (Voos, 2009). Among the proteolytic enzymes impli-
cated in the mitochondrial quality control system, there are
several ATP-dependent proteases such as Yme1L and m-AAA
proteases located in the inner membrane, or ClpP and Lonp1
that carry out their functions in the matrix (Koppen and
Langer, 2007). The functional relevance of these mitochon-
drial enzymes is underscored by the finding that deficiencies
in m-AAA proteases SPG7 and AFG3L2 are responsible for
important neurodegenerative diseases such as hereditary
spastic paraplegia or a dominant form of spinocerebellar
ataxia (Casari et al, 1998; Di Bella et al, 2010).
In addition to the key role of mitochondrial proteases in
the quality control system characteristic of these organelles,
these enzymes may also regulate the activity of some mito-
chondrial proteins through their ability to perform highly
specific reactions of proteolytic processing, which contribute
to the maturation or inactivation of these substrates. This
may be the case of OMA1, a proteolytic enzyme located in the
inner mitochondrial membrane, which was first identified in
yeast as a protease with overlapping activities with m-AAA
proteases (Kaser et al, 2003). OMA1 is a zinc metalloprotease
of the M48 family, which exhibits multiple transmembraneReceived: 20 September 2011; accepted: 17 February 2012
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domains and significant amino-acid sequence similarity with
FACE1/ZMPSTE24, a protease involved in the processing of
prelamin-A and whose mutations cause premature ageing
disorders (Navarro et al, 2005; Varela et al, 2005, 2008). Yeast
OMA1 seems to play a role in mitochondrial quality control
through a mechanism similar to that of m-AAA proteases,
although in an ATP-independent manner. This activity has
been proposed to be part of a salvage system of quality
control, reminiscent of that performed in Escherichia coli by
HtpX, a stress protease with overlapping activities with the
AAA protease FtsH (Shimohata et al, 2002). Recently, a series
of in vitro studies have permitted the conclusion that OMA1,
in collaboration with m-AAA protease isoenzymes, contri-
butes to the proteolytic processing of OPA1 (optic atrophy 1),
a dynamin-related GTPase involved in mitochondrial inner
membrane fusion as well as in the regulation of mitochon-
drial morphology and in the protection of cells from apopto-
sis (Ehses et al, 2009; Head et al, 2009).
To further characterize the in vivo role of this mitochon-
drial metalloprotease, we have generated mutant mice defi-
cient in OMA1. These mice are viable and fertile, but exhibit a
marked obesity with metabolic alterations, reduced energy
expenditure and altered thermogenic response. Furthermore,
we have found that OMA1 plays an essential and non-
redundant role in the in vivo proteolytic inactivation of the
GTPase OPA1. Finally, we describe studies of mitochondrial
activity and function in brown fat tissue and primary adipo-
cytes deficient in OMA1. On the basis of these findings, we
propose that OMA1 participates in mitochondrial quality
control regulating mitochondrial dynamics, and its absence
induces mitochondrial dysfunctions, which have an impor-
tant impact on mouse metabolic homeostasis.
Results
Generation of mice deficient in OMA1
To evaluate the in vivo roles of OMA1 mitochondrial protease,
we engineered a targeting vector to generate a null allele of
Oma1. This vector was designed to replace exon 2 of the
Oma1 gene with a neo cassette (Supplementary Figure S1A).
The linearized construct was electroporated into G4 embryo-
nic stem cells and after homologous recombination, we
obtained seven positive targeted clones that were used to
generate chimeric mice. These mice were then bred to
C57BL/6 mice to generate heterozygous mice. After inter-
crossing these heterozygous mice, we generated Oma1/
animals at the expected Mendelian ratio. Homozygosity for
the mutation was confirmed by Southern blot and PCR
analysis (Supplementary Figure S1B and C).
Despite the Oma1 deficiency, these mutant mice developed
normally, with males and females being fertile, and their
survival rates indistinguishable from those of their wild-type
littermates (Supplementary Figure S2A). During the time
period we studied the animals, we did not observe any
physical indicators of neurological abnormalities. Moreover,
histopathological analysis of the brain, specifically the hip-
pocampus, from 18-month-old mice did not reveal any neu-
ronal loss, nor increment in ubiquitin staining in Oma1-
deficient mice compared with their littermates controls.
Finally, all samples analysed for both genotypes displayed
changes consistent with normal ageing (Supplementary
Figure S2B). These findings demonstrate that OMA1 is
dispensable for embryonic and adult mouse development,
as well as for normal growth and fertility, possibly due to
functional redundancy with other peptidases present in the
inner membrane of mitochondria.
Diet-induced obesity in Oma1/ mice
In the course of phenotypic characterization of Oma1-defi-
cient mice, we noticed a significant increase in the body
weight of Oma1/ mice as compared with their wild-type
littermates kept on standard chow (Supplementary Figure
S2C). This observation encouraged us to evaluate a putative
role for OMA1 in adipose tissue biology. Accordingly, wild-
type and Oma1 knockout mice were fed a high-fat diet and
total body weights were determined for 24 weeks. We started
our study with 4-week-old mice, which displayed similar
weights and adipose deposit composition in males and
females of each genotype (Supplementary Figure S2D). At
8 weeks, we observed significant weight differences in Oma1/
males when compared with controls, and these marked changes
continued until the end of the experiment. In the case of
Oma1/ females, there was also an increase of weight when
compared with the corresponding controls, but lower than in
male mice (Figure 1A and B). Statistical analysis revealed that
the gain of weight observed at the end of the experiment was
significantly higher in both male and female mice deficient in
Oma1 than in their littermate controls (Figure 1C).
To determine whether the increase of body weight
observed in Oma1-deficient mice was due to an increase in
fat content, gonadal and subscapular fat pad deposits were
separately weighted. We only detected an increase of gonadal
fat pads weight and their weight normalized to total body
weight in Oma1-null mice (Figure 1D and E), whereas sub-
scapular fat pads and their weight relative to total body
weight did not reach statistical significant differences.
Histological analysis of white adipose tissue (WAT) from
gonadal and subcutaneous deposits showed a marked adipo-
cyte hypertrophy in Oma1/ mice (Figure 1F), which was
confirmed by morphometric measurement of adipocyte area
(Figure 1G). Analysis of brown adipose tissue (BAT) of
Oma1-deficient mice did not show any significant alteration
in fat content (Supplementary Figure S3A), indicating that the
obesity-induced phenotype was only related to WAT hyper-
trophy. Interestingly, those Oma1/ mice exhibiting the
most severe obesity phenotype often presented granuloma-
like lesions in the intestinal mesenteric fat. Further histolo-
gical analysis of these granulomatous lesions revealed the
presence of fat necrosis foci containing foamy histiocytes and
cholesterol crystals (Supplementary Figure S3B). Similar
lesions have been described previously as crown-like struc-
tures, which appear to manifest as a result of increased
inflammation and adipocyte cell death (Cinti et al, 2005).
All these findings suggest that the absence of OMA1 protease
leads to profound alterations in WAT homeostasis after
nutritional challenges.
Metabolic changes in Oma1/ mice
To further evaluate the phenotypic alterations observed in
Oma1/ mice, we performed an analysis of biochemical
parameters and metabolic enzymes in the liver of these
mutant mice under both standard and high-fat diet. First,
and because in many animal models of obesity blood glucose
tends to be above normal due to obesity-induced insulin
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resistance, we measured blood glucose levels in Oma1/
adult mice, but we did not observe any differences with
control mice in both standard and high-fat diet conditions
(Figure 2A). Furthermore, analysis of liver parameters did not
reveal significant differences in levels of hepatic transami-
nases under standard chow diet. However, under high-fat
diet, we observed an increment in the levels of both Ala- and
Asp-transaminases (Figure 2B). Total levels of cholesterol in
mutant mice did not exhibit significant differences with those
of control animals under chow and high-fat diet (Figure 2C).
Nevertheless, levels of triglycerides were significantly higher
in Oma1/ mice compared with littermate controls, in both
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Figure 1 Increase of body weight and fat content in Oma1/mice after diet-induced obesity. (A) Photograph of representative Oma1þ /þ and
Oma1/ mice after high-fat diet induced obesity. (B) Body weight curves of males and females of Oma1þ /þ (~) and Oma1/ (&) mice
(n¼ 8–12). (C) Lean body mass in the same animals. (D) Gonadal and subscapular fat mass and (E) gonadal and subscapular fat mass as a
percentage of total body weight of the same animals at the end of the experiment. (F) H&E sections of gonadal WATand skin of Oma1þ /þ and
Oma1/mice. Original magnifications WAT:  200; skin:  40. Scale bar: 60mm. (G) Mean of adipocyte area in gonadal WATand skin. Results
are mean±s.e.m. (n¼ 6–12). *Po0.05; **Po0.01; ***Po0.001.
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standard and high-fat diet (Figure 2D). Consistent with this,
Oil Red O staining revealed a marked steatosis in the liver of
Oma1/ mice maintained on a normal chow diet, which
increased significantly under a high-fat diet (Figure 2E).
Levels of free fatty acids were comparable between genotypes
on both diets (Figure 2F). Interestingly, analysis of insulin
and leptin plasma levels showed different patterns under
standard and high-fat diet. Thus, under standard rodent
chow, both insulin and leptin plasma levels were reduced
in mutant mice. However, under high-fat diet, insulin levels
did not show differences despite the increment levels in
control and mutant mice. Furthermore, leptin levels were
significant enhanced as expected in an obese mouse model
(Figure 2G and H).
The absence of hyperglycaemia in Oma1-deficient mice,
together with their low insulin levels under standard chow
diet, suggested the possibility of an increased insulin sensi-
tivity of Oma1/ mice. Accordingly, intraperitoneal glucose
tolerance tests (IPGTTs) revealed that Oma1/ mice showed
improved glucose clearance compared with control mice
(Figure 2I). Intraperitoneal insulin tolerance tests (IPITTs)
confirmed that Oma1/ mice presented increased insulin
sensitivity (Figure 2J), which is consistent with their low
insulin levels. Remarkably, these advantages in glucose
metabolism were lost when Oma1-deficient mice were fed a
high-fat diet. Thus, the metabolic tests in mutant mice
showed a decrease in glucose tolerance and the same insulin
insensitivity than control mice (Figure 2I and J, lower
panels). Insulin tolerance was also analysed at 8 weeks,
with animals displaying similar insulin responses to those
observed at 12 weeks (data not shown). In addition, obese
Oma1/ mice showed the same higher levels of insulin than
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Figure 2 Lipid metabolism and glucose tolerance alterations in Oma1/ mice under standard chow and high-fat diet. Analysis of serum and
plasma parameters of Oma1þ /þ and Oma1/mice (12–20 weeks old, n¼ 6–12 for each group). Mice were fed on standard chow and high-fat
diet, and analysis was determined after an overnight fast. (A) Blood glucose levels in Oma1þ /þ and Oma1/ mice. (B) Serum levels of
alanine aminotransaminase (ALT) and aspartate aminotransaminase (AST), (C) cholesterol and (D) triglycerides. (E) Oil Red O staining of
histological sections of liver from Oma1þ /þ and Oma1/ mice under chow diet (CD) and high-fat diet (HFD). Scale bar: 20 mm. Levels of
(F) free fatty acids, (G) insulin and (H) leptin in plasma of Oma1þ /þ and Oma1/ mice. (I) IPGTT and (J) IPITT in wild-type and Oma1/
male mice (8–12 weeks old, n¼ 6–8). AUC, area under the curve (arbitrary units). Bars represent mean values±s.e.m. ns denotes no
significant difference. *Po0.05.
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controls (Figure 2F), which explains the observed insulin
insensitivity.
To further investigate these metabolic alterations observed
in Oma1-deficient mice, we performed oligonucleotide-based
microarrays to analyse transcriptional changes in adipose
tissue from Oma1/ mice kept under high-fat diet. As can
be seen in Supplementary Table S1, we found a marked
up-regulation in the expression of genes encoding proteins
related with lipid metabolism and transport such as fatty-acid
binding protein 1 (FABP1) and several apolipoproteins and
cytochromes. Further, bioinformatic analysis revealed that a
number of the up-regulated genes in Oma1-deficient mice
are associated with two metabolic pathways (peroxisome
proliferator-activated receptors a and g, and retinol pathway),
which can be related to the obesity phenotype observed in
these mutant mice (Supplementary Figure S4). Collectively,
these results indicate that mutant mice deficient in OMA1
mitochondrial protease exhibit significant alterations in
lipid metabolism, characterized by an increase in triglycer-
ides and hepatic steatosis, as well as an improved glucose
clearance likely derived from an increased sensitivity to
insulin.
Energy balance and thermogenesis are altered in
Oma1-deficient mice
To determine the possible causes of the obesity and metabolic
dysfunction observed in Oma1-deficient mice, we performed
analyses of their food-intake and energy balance in mice
maintained on a control chow diet. We did not find significant
differences in food-intake of Oma1/mice relative to control
littermates (Figure 3A). However, indirect calorimetry studies
indicated that Oma1-deficient mice showed reduced oxygen
consumption and CO2 production, which correlated with a
significant reduction in heat production in these mice (Figure
3B–D). These alterations occurred in the absence of changes
in respiratory quotient values (Figure 3E) and could not be
explained by changes in ambulation (Figure 3F). Thus, we
decided to study thermogenic activity of BATunder basal and
cold-stress conditions. As expected, wild-type mice showed
an increase in body temperature at night under basal condi-
tions (221C), which was not observed in Oma1-deficient mice
(Figure 3G). To further evaluate their adaptive thermogenic
response, Oma1þ /þ and Oma1/ mice were subjected to
cold exposure at 41C monitoring their temperature for 12 h.
As can be seen in Figure 3H, Oma1/ mice showed a
significant decrease in body core temperature when com-
pared with controls from 3 to 12 h. We analysed UCP1 protein
levels after cold-stress but we did not find any differences,
indicating that the observed failure in thermogenic response
was not due to a decrease in UCP1-mediated uncoupling
(data not shown). However, histological analysis of BAT
showed that while control mice depleted lipid droplets
under cold-stress, Oma1-deficient animals retained most of
them (Figure 3I and J). Taken together, these results indicate
that Oma1 ablation causes reduced energy expenditure under
stress conditions, which may explain the susceptibility of
these mice to obesity and their impaired adaptive thermo-
genic response.
Next, we examined whether reduced respiration of Oma1-
deficient mice could be explained by alterations in the
expression of genes coding for mitochondrial proteins or for
the nuclear co-activator PGC1a, an essential transcriptional
regulator of mitochondria and oxidative metabolic pro-
grammes (Finck and Kelly, 2006; Uldry et al, 2006;
Fernandez-Marcos and Auwerx, 2011). To this end, we
obtained tissues from wild-type and Oma1-deficient mice
chronically subjected to a high-fat diet (20 weeks) and
analysed the expression of selected genes by real-time
qPCR. BAT samples showed reduced expression of b-oxida-
tion genes, Cpt1b and Vlcad in the Oma1-deficient group
(Table I). Livers from Oma1-deficient mice showed a reduced
expression of Ndufa9, Uqcrc2 and CoxIV (Table I).
Furthermore, we detected increase in Pgc1a and decrease in
Pgc1b, together with an increase in lipogenic genes Fasn and
Scd1 in Oma1-deficient mice compared with controls
(Table I). In addition, we also detected reduced expression
of Sdha and Atp5a1 in skeletal muscle from Oma1-null mice
(Supplementary Table S2). Collectively, these data indicate
that Oma1 deficiency causes a reduced expression of nuclear
genes encoding mitochondrial proteins, decrease in b-oxida-
tion genes and increase in lipogenic genes, which may
explain the low oxygen consumption and obesity phenotype
of these animals. Notably, Oma1 deletion also led to a
marked decrease in the expression of genes encoding proteins
involved in mitochondrial fusion (Mfn2 or Opa1) or in
mitochondrial fission (Drp1). In fact, Mfn2 was markedly
down-regulated in BAT and WAT from Oma1-null mice,
whereas Opa1 was down-regulated in BAT, WAT and skeletal
muscle (Table I; Supplementary Table S2). Additionally, Drp1
was down-regulated in BAT, skeletal muscle and liver from
Oma1-deficient mice (Table I; Supplementary Table S2).
Alteration of OPA1 processing in Oma1/ mice
Recent in vitro studies have shown that OMA1 cooperates
with m-AAA proteases in the proteolytic inactivation of OPA1
(Ehses et al, 2009; Head et al, 2009). To evaluate how mouse
OMA1 induces this proteolytic inactivation, we first com-
pared the levels of the different isoforms of OPA1 in murine
embryonic fibroblasts (MEFs) from Oma1þ /þ and Oma1/
mice. In Oma1þ /þ cells, we detected the five characteristic
isoforms of OPA1 (labelled a–e) (Figure 4A). After treatment
of these cells with the protonophore carbonylcyanide
m-chlorophenylhydrazone (CCCP), an inducer of loss of
mitochondrial membrane potential, we detected the conver-
sion of bands b–e (Figure 4A). This proteolytic event involves
the processing of large (L-OPA1) to short (S-OPA1) isoforms
of OPA1 and protects cells from mitochondrial fusion under
stress conditions. Interestingly, we could not detect the
S-OPA1 isoform corresponding to band c in Oma1/ MEFs,
concomitant with a decrease in the production of band e
(Figure 4A). Furthermore, we did not observe the cleavage of
L-OPA1 (band b) to S-OPA1 isoforms (band e) in Oma1/
cells treated with CCCP (Figure 4A). Similar results were
obtained when cells were treated with staurosporine, a
known apoptosis inducer, or with oligomycin, an inhibitor
of ATP synthesis (Figure 4B). Analysis of tissue samples from
Oma1-deficient mice also revealed alterations in OPA1 pro-
cessing, characterized by the absence of isoform c in all cases
(Supplementary Figure S5A and B). Interestingly, analysis of
WAT samples from high-fat diet showed an increase in iso-
form e and a decrease in L-OPA1 isoforms in control mice, a
characteristic pattern of stress conditions, whereas Oma1-
deficient mice maintained all L-OPA1 isoforms intact
(Supplementary Figure S5C). Accordingly, we conclude that
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OMA1 mediates the in vivo cleavage and inactivation
of OPA1.
To further investigate the molecular consequences of
Oma1 deletion on mitochondrial structure and function, we
examined mitochondrial morphology in immortalized MEFs
from Oma1þ /þ and Oma1/ mice. We observed that
Oma1/ MEFs show a lower percentage of mitochondrial
fragmentation than control MEFs, as well as an increase in
tubular connections (Figure 4C and D; Supplementary Figure
S5D). We also examined the mitochondrial morphology of
–
–
–
–
–
–
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Figure 3 Decrease of energy expenditure and impaired thermogenesis in Oma1/ mice. (A) Food-intake of 2-month-old Oma1þ /þ and
Oma1/ mice kept on standard rodent chow (n¼ 6). (B) Whole body oxygen consumption (ACC O2), (C) carbon dioxide production (ACC
CO2), (D) heat production, (E) respiratory quotient (RQ) and (F) ambulatory movement of 2-month-old Oma1
þ /þ and Oma1/ mice during
dark period of 3 days kept on standard rodent chow (n¼ 6–8). (G) Basal rectal temperature of Oma1þ /þ and Oma1/ mice measured during
daytime (1000 hours) and night (2200 hours) for 3 consecutive days (n¼ 5). (H) Body temperature curve of 2-month-old Oma1þ /þ and
Oma1/ mice exposed to 41C during 12 h (n¼ 6). (I) Representation of BAT histology stained with H&E of Oma1-deficient mice and controls
before and after cold exposure for 3 h. Scale bar: 50 mm. (J) The cumulative area occupied by all lipid droplets in each of the tissue sections was
determined using image J and presented as a percentage of the total area analysed (n¼ 4). *Po0.05; **Po0.01; ***Po0.001.
Metabolic control by mitochondrial protease OMA1
PM Quiro´s et al
The EMBO Journal &2012 European Molecular Biology Organization6
MEFs from mutant and control mice after treatment with
CCCP. We observed that the CCCP-induced mitochondrial
fragmentation is lower in Oma1/ cells than in their corre-
sponding controls (Figure 4E). Likewise, mutant cells pre-
dominantly maintain the tubular network morphology when
compared with cells from wild-type mice (Figure 4E).
Furthermore, after treatment with this inducer of membrane
potential loss, we still observed a significant percentage of
Oma1/ cells that conserved the highly connected mito-
chondrial morphology (Figure 4E). Collectively, these results
provide evidence that Oma1/ cells are unable to perform
the protease-mediated process of inactivation of OPA1 and
are also refractory to the stress signals induced by CCCP,
maintaining the mitochondrial tubular network morphology.
It has been previously reported that OPA1 is cleaved
concomitantly with cytochrome c release during apoptosis
(Cipolat et al, 2006; Baricault et al, 2007; Griparic et al, 2007).
As can be seen in Figure 4B, proteolytic processing of OPA1 in
Oma1-deficient cells was blocked after induction of apoptosis
with staurosporine. To further evaluate the putative impact of
Oma1 deficiency on apoptosis, Oma1/ cells were treated
with staurosporine and the number of apoptotic cells was
determined. The percentage of pyknotic nuclei was signifi-
cantly lower in Oma1-deficient cells than in controls
(Figure 4F). Western blot analysis of PARP cleavage and
activated caspase-3 levels confirmed the decreased sensitivity
to apoptosis of Oma1-deficient cells after treatment with
staurosporine and etoposide (Figure 4G). Taken together,
these results indicate that Oma1 deficiency impairs cellular
sensitivity to apoptosis.
Analysis of mitochondrial function in Oma1/ cells
To determine whether the deficiency in OMA1 metalloprotei-
nase has any effect on mitochondrial activity, we performed a
series of functional experiments using Oma1/ MEFs. First,
we assessed the proliferation rate of Oma1-deficient MEFs
but we did not observe significant differences with control
cells (Supplementary Figure S6A). Similarly, we did not find
significant differences in OXPHOS function in the absence of
OMA1. In fact, coupled and CCCP-uncoupled respiration
rates were comparable between Oma1þ /þ and Oma1/
cells, as well as oligomycin- and KCN-insensitive oxidation
(Supplementary Figure S6B). Furthermore, the ratio between
uncoupled and coupled respiration (Supplementary Figure
S6C) and the polarography measurements of mitochondrial
complexes did not show significant differences between
Oma1þ /þ and Oma1/ cells (Supplementary Figure S6D).
Moreover, ATP levels in mutant cells were very similar to
those of control cells under both basal and oxidative stress
conditions (Supplementary Figure S6E). Collectively, these
results indicate that OMA1 does not play a major role in the
maintenance of OXPHOS function. Analysis of mitochondrial
inner membrane potential (DCm) using TMRM fluorescence
probe did not show differences between Oma1þ /þ and
Oma1/ cells, in neither control nor CCCP-stimulated
uncoupling conditions (Supplementary Figure S6F).
However, we could detect a significant loss of mtDNA in
Oma1-deficient cells (Supplementary Figure S6G). This
decrease could not be explained by a decrease in mitochondrial
mass as the activity of citrate synthase (Supplementary Figure
S6H), a known marker of mitochondrial mass, and MitoTracker
flow cytometry analysis (Supplementary Figure S6I) was com-
parable in cells from both genotypes. Thus, it is reasonable to
speculate that the loss of OMA1 alters the copy number of
mtDNA, likely as a consequence of defective OPA1 processing
and the subsequent changes in the mitochondrial morphology.
To study mitochondrial function in tissues, we analysed
mitochondrial respiration rates in mitochondria isolated from
livers of Oma1þ /þ and Oma1/ mice on control and high-
fat diet. Thus, we measured the respiration rates in states 3
and 4 using two different combinations of substrates (gluta-
mateþmalate and succinate). Similar to the above cell
analysis, we did not observe differences between the two
genotypes in respiration control rate or ATP synthesis per O2
consumed—represented as P/O rate—under control and
high-fat diets (Figure 5A and B; Supplementary Figure
S7A). These results demonstrate that abnormalities observed
in Oma1-deficient mice were not due to defects in the
OXPHOS system. To analyse other possible pathways that
could explain the phenotype observed in Oma1-deficient
mice, we assessed fatty-acid utilization in the BAT and liver
of Oma1/ mice on both control and high-fat diets. As
shown in Figure 5C and D, Oma1-deficient mice on a high-
fat diet had a significant decrease in fatty-acid b-oxidation in
BAT and liver compared with wild-type controls. Under a
control diet, a significant decrease in fatty-acid utilization
was found only in the BAT of Oma1/ mice, indicating that
the dysfunction in b-oxidation was due to primary defects in
BAT and not a result of an inflammatory state caused by the
obesity phenotype. However, and because the impaired
b-oxidation was only observed in the livers of Oma1þ /þ
on a high-fat diet, we cannot exclude that inflammation may
contribute to defective fatty-acid utilization in this tissue.
Table I Expression of mitochondrial genes in BAT and liver of
Oma1+/+ and Oma1/ under high-fat diet
Brown adipose tissue Liver
Oma1+/+ Oma1/ Oma1+/+ Oma1/
Mitochondrial dynamics
Mfn2 1±0.18 0.55±0.09* 1±0.25 0.64±0.11
Opa1 1±0.37 0.47±0.05 1±0.12 0.94±0.30
Drp1 1±0.17 0.56±0.07* 1±0.21 0.41±0.07*
OXPHOS genes
Ndufa9 1±0.30 0.93±0.07 1±0.11 0.67±0.14*
SdhA 1±0.42 0.64±0.10 1±0.14 1.18±0.33
Uqcrc2 1±0.39 0.84±0.08 1±0.16 0.61±0.12*
CoxIV 1±0.29 1.13±0.12 1±0.05 0.77±0.09*
Atp5a1 1±0.35 0.73±0.05 1±0.12 0.91±0.18
Metabolic regulators
Pgc1a 1±0.11 0.82±0.24 1±0.01 1.62±0.19*
Pgc1b 1±0.16 0.64±0.12 1±0.19 0.53±0.07*
b-Oxidation genes
Mcad 1±0.17 0.83±0.13 1±0.08 0.82±0.17
Vlcad 1±0.14 0.65±0.65* 1±0.11 0.92±0.14
Cpt1a 1±0.15 1.07±0.21
Cpt1b 1±0.08 0.67±0.13*
Cpt2 1±0.11 0.82±0.24 1±0.10 0.84±0.11
Lipogenic genes
Fasn 1±0.11 0.82±0.24 1±0.14 2.79±0.45**
Acc1 1±0.06 0.91±0.21 1±0.06 1.27±0.13
Scd1 1±0.13 0.81±0.04 1±0.11 2.16±0.47*
Gene expression relative to b-actin. Data represent mean±s.e.m. of
at least five mice per group. *Po0.05; **Po0.01.
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Additionally, we measured citrate synthase activity in both
liver and BAT from Oma1þ /þ and Oma1/ mice on control
and high-fat diet, and did not find differences under these
conditions between the two genotypes (Supplementary
Figure S7B and C). These results demonstrate that differences
in b-oxidation were due to specific mitochondrial defects and
not attributable to a decrease in mitochondrial mass.
Having identified a significant inability of Oma1-deficient
mitochondria to oxidize fatty acids under control and high-fat
diets in BAT, we next chose to explore the impact of Oma1
ablation on the morphology of mitochondria in this tissue by
electron microscopy. Measurements of mitochondrial size
showed a significant increase in mitochondrial area from
Oma1/ BAT compared with controls (Figure 5E and F).
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Figure 4 Impaired OPA1 processing induces mitochondrial morphology alterations and apoptosis resistance in Oma1/ mice. (A) Western
blot analysis of OPA1 processing in Oma1þ /þ and Oma1/MEFs after treatment with 20mM of CCCP for 60min. (B) Western blot analysis of
OPA1 processing after treatment of Oma1þ /þ and Oma1/ MEFs with 20mM CCCP, 20mM oligomycine (OLG) and 1 mM staurosporine (STS)
during 3 h. (C) Confocal images of Oma1þ /þ and Oma1/ MEFs in control cells and after CCCP treatment. Insets represent characteristic
mitochondrial morphologies observed in each situation. Scale bar: 10 mm. (D) Mitochondrial morphology of Oma1þ /þ and Oma1/. MEFs
were visualized after transfection with a vector containing mito-DsRed, and (E) after treatment with 20mM of CCCP during 3 h. More than 100
cells were scored. Bars represent mean values±s.e.m. and are shown as a percentage of the total, of three independent experiments
(**Po0.01). (F) Percentage of apoptotic cells was determined by counting pyknotic nuclei after treatment of Oma1þ /þ and Oma1/ MEFs
with 1mM staurosporine during each time point. More than 150 cells were counted. Bars represent mean values±s.e.m. and are shown as a
percentage of the total, of three independent experiments (**Po0.01). (G) Western blot analysis of PARP and activated caspase-3 as apoptosis
markers in Oma1þ /þ and Oma1/ MEFs, after treatment of these cells with 1mM staurosporine and 100mM etoposide (ETP) during 3 and
16h, respectively. Figure source data can be found in Supplementary data.
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Figure 5 Mitochondrial alterations in liver and BATafter obesity and cold-stress. Analysis of OXPHOS function in mitochondria isolated from
liver of Oma1þ /þ and Oma1/ mice on control and high-fat diet. (A) Mitochondrial respiration control rate (RCR) and (B) P/O ratio, using
glutamateþmalate or succinate as substrates. Reduced fatty-acid utilization in Oma1-deficient mice. Mitochondrial fatty-acid oxidation was
measured by the incubation of 14C-palmitate (100 mM) in liver (C) and BAT (D) extracts from mice under control diet and high-fat diet (n¼ 4).
(E) Electron microscopy (EM) images from BATof Oma1þ /þ and Oma1/ mice on control and cold-stress. Scale bar: 0.4mm. Mitochondrial
morphology quantification in EM was measured with ImageJ, represented as (F) area of mitochondria and (G) number of mitochondria per
field, using at least 12 different pictures of each condition. (H) Western blot analysis of OPA1, MFN2 and DRP1 in BAT samples extracted from
mice after control and cold-stress treatment. Bars represent mean values±s.e.m. *Po0.05; **Po0.01; ***Po0.001. Figure source data can be
found in Supplementary data.
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Moreover, we found that after cold-stress, Oma1þ /þ BAT
increased the size of mitochondria while Oma1/ BAT
maintained an identical mitochondrial size (Figure 5F). All
of these changes were produced without significant differ-
ences in the mitochondrial number between control and
Oma1-deficient mice (Figure 5G). Focusing on OPA1 proces-
sing after cold-stress, Oma1þ /þ mice displayed a small but
appreciable loss of isoform ‘a’ and a clear accumulation of
isoform ‘c’, the isoform exclusively generated by OMA1 in
response to cold-stress (Figure 5H). This pattern of OPA1
processing was absent in Oma1/ BAT, indicating that cold-
stress initiates OMA1-mediated processing of OPA1.
Moreover, while OPA1 remodelling was detected in BAT,
neither MFN2 nor DRP1 proteins showed a clear difference
in either condition. Collectively, these results indicate that
Oma1-null mice are unable to develop the appropriate mito-
chondrial dynamic response required for cold-stress-induced
thermogenesis.
OMA1-OPA1 system is necessary for brown adipocytes
function
To explore the connection observed in BAT between OPA1
processing by OMA1 and b-oxidation function, we next
analysed fatty-acid utilization in primary brown adipocytes
from Oma1þ /þ and Oma1/ mice. Brown preadipocytes
were isolated from newborn mice, immortalized and differ-
entiated into mature brown adipocytes. We then analysed
palmitate oxidation rates as an indicator of b-oxidation func-
tion in Oma1þ /þ and Oma1/mature brown adipocytes. In
agreement with our experiments in BAT (Figure 5D), Oma1-
deficient adipocytes displayed significantly lower palmitate
oxidation rates in comparison to wild-type control cells
(Figure 6A). Next, to delineate the importance of OPA1 for
brown adipocyte function, we ablated OPA1 protein levels in
Oma1þ /þ using siRNA and then analysed palmitate oxida-
tion rates. This protocol involved first differentiating the
primary brown preadipocytes for 2 days with insulin, T3,
IBMX, dexamethasone and indomethacin, and then transfect-
ing the cells with an siRNA targeting OPA1 mRNA or a
scrambled control. The cells were maintained for a further
72 h with insulin and T3 to complete adipocyte differentiation
and then analysed for palmitate oxidation rates. This
approach reduced OPA1 protein levels by B75% in the
final mature brown adipocytes (Figure 6B). Interestingly,
knockdown of OPA1 decreased palmitate oxidation rates by
B25% in Oma1þ /þ brown adipocytes compared with cells
transfected with the scrambled siRNA (Figure 6C). This
indicates that OPA1 is required for the correct functioning
of brown adipocyte b-oxidation. Further, to specifically
demonstrate the relevance of OPA1 processing by OMA1 in
brown adipocyte function, we restored OPA1 in these cells by
reintroducing wild-type OPA1 or a mutant OPA1 isoform not
cleavable by OMA1. Brown adipocytes were transfected with
OPA1 siRNA to remove endogenous OPA1 protein as outlined
previously, then 24 h later, we transfected a mammalian
expression vector containing a wild-type full-length cDNA
of OPA1 (OPA1-S1) or a mutant cDNA isoform of OPA1
without the S1 cleavage site that is utilized by OMA1
(OPA1-DS1) (Ishihara et al, 2006). Both constructs were
insensitive to the siRNA targeting mouse Opa1 due to their
human origin and lack of homology in the targeted region
and contained a Flag epitope for detection by western blot
(Figure 6B). Thus, reintroduction of full-length OPA1 in
adipocytes partially restored the levels of palmitate oxidation
(Figure 6C). However, mutant OPA1-DS1 did not demonstrate
a similar ability to increase the levels of palmitate oxidation,
displaying similar oxidation rates to those observed in OPA1-
depleted cells (Figure 6C). These results indicate that
b-oxidation in brown adipocytes requires the OMA1-OPA1
system, and an absence of OPA1 or its proteolytic regulator
OMA1, impairs mitochondrial function.
In summary, our results indicate a pivotal role for the
OMA1 protease in mitochondrial homeostasis by regulating
the mitochondrial dynamics that is essential for lipid meta-
bolism as well as to maintain body temperature and energy
expenditure under cold-stress conditions.
Discussion
We describe herein the generation and phenotypic character-
ization of mutant mice deficient in OMA1, a mitochondrial
metalloprotease proposed to be involved in protein quality
control. Despite the wide tissue distribution of OMA1, the
disruption of this gene does not cause the severe abnormal-
ities observed in mice deficient in other mitochondrial
proteases such as SPG7, AFG3L2 or PARL (Ferreirinha et al,
2004; Cipolat et al, 2006; Maltecca et al, 2008). However,
further analysis of Oma1/ mice revealed an unexpected
contribution of this protease to metabolic homeostasis.
In fact, Oma1-deficient mice exhibit a progressive increase
in body weight when compared with control animals, and
these differences are further enhanced when mice from both
genotypes are maintained on a high-fat diet. Histological
analysis showed a marked hypertrophy of adipocytes from
Oma1/ mice. These mutant animals also exhibited hepatic
steatosis as well as a significant increase in plasma triglycer-
ides and a decrease in circulating leptin and insulin levels.
Moreover, glucose and insulin tolerance tests revealed that
Oma1-null mice display improved glucose tolerance and
increased insulin sensitivity. Furthermore, after high-fat
diet induced obesity, Oma1-deficient mice lost glucose toler-
ance protection and developed insulin insensitivity, display-
ing higher levels of leptin than those found in obese
controls. Finally, hepatic steatosis and triglyceride levels
were also dramatically enhanced in mutant mice after high-
fat diet.
The finding of this array of metabolic changes in Oma1/
mice prompted us to explore their putative links to the
absence of this mitochondrial metalloproteinase, which had
not been previously associated with metabolic homeostasis.
In this regard, there is growing evidence that a number of
metabolic disorders are caused by alterations of mitochon-
drial function and dynamics (Detmer and Chan, 2007; Suen
et al, 2008; Hyde et al, 2010; Westermann, 2010). There are
many proteins implicated in the regulation of the appropriate
balance between mitochondrial fission and fusion. In mam-
mals, mitochondrial fission is largely controlled by the
dynamin-related GTPase DRP1 (Chang and Blackstone,
2010), whereas mitochondrial fusion mainly depends on the
activity of three large GTPases, the mitofusins (MFN1 and
MFN2) and OPA1 (Hoppins and Nunnari, 2009; Zorzano et al,
2010). On the basis of these previous findings, we speculated
that the absence of OMA1 could alter the levels of some
of these proteins involved in modulating mitochondrial
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dynamics, shifting the balance towards fusion or fission
events, and finally resulting in the metabolic alterations
observed in Oma1-mutant mice. In fact, our proteomic ana-
lysis of cells and tissues from Oma1/ mice revealed that
OMA1 plays an in vivo non-redundant role in the proteolytic
processing of OPA1, which leads to its functional inactivation
under stress conditions, thus extending recent in vitro find-
ings showing that OPA1 can be targeted by OMA1 (Ehses
et al, 2009; Head et al, 2009). There are at least five OPA1
isoforms in mammalian cells, including two long forms (L-
OPA1) and three short isoforms (S-OPA1) (Duvezin-Caubet
et al, 2006; Ishihara et al, 2006; Griparic et al, 2007; Song
et al, 2007). The precise molecular balance between these
long and short isoforms is necessary for mitochondrial fusion
to occur. However, under stress conditions such as loss of
mitochondrial membrane potential, low levels of mitochon-
drial ATP or induction of apoptosis, L-OPA1 isoforms are
cleaved to S-OPA1 isoforms and mitochondrial fusion is
blocked (Song et al, 2007). Our finding that Oma1/ MEFs
lack one isoform (‘c’) and have a decrease in another isoform
(‘e’) of the three S-OPA1 isoforms, clearly indicate that OMA1
is responsible for the in vivo proteolytic processing of L-OPA1
isoforms. Notably, even under stress conditions, Oma1/
cells display the same pattern of OPA1 isoforms characterized
by the lack of processing of L-OPA1, which finally results in
the shift of mitochondrial dynamics towards fusion events.
Tissue samples from Oma1-deficient mice also lack one
S-OPA1 isoform in all cases (isoform ‘c’), although the
pattern of OPA1 bands exhibits some differences with that
of MEFs, which can be due to variations in compensatory or
redundant proteolytic activities operating in the different cells
and tissues from Oma1-null mice under normal conditions.
The OPA1-processing deficiency was also clearly evident in
BAT samples from mutant mice after cold-stress and in WAT
samples after high-fat diet, as assessed by the maintenance of
all L-OPA1 isoforms and the absence of any increase in S-
OPA1 bands. Collectively, these results demonstrate that both
cells and tissues from Oma1-null mice exhibit an in vivo
impairment of OPA1 inactivation, which is especially signifi-
cant under stress conditions. Consistent with this proteolytic
processing deficiency, Oma1/-deficient cells show an in-
crease of highly connected and less-fragmented mitochondria
when compared with control cells. Likewise, after treatment
of cells with CCCP, which induces loss of mitochondrial
membrane potential, most mitochondria from Oma1-defi-
cient cells maintain their archetypal tubular network,
whereas those present in control cells show a fragmented
morphology. We found the same protection against mito-
chondrial fission when Oma1-mutant cells were treated
with a respiratory chain inhibitor such as oligomycin or
with an apoptosis inducer such as staurosporine, demonstrat-
ing that even under different stress conditions, the absence of
OMA1 imposes a pro-fusion phenotype in mitochondria from
Oma1-mutant mice.
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Figure 6 b-Oxidation in brown adipocytes depends on OMA1 and OPA1 function. (A) Analysis of palmitate oxidation rate in brown adipocytes
obtained from Oma1þ /þ and Oma1/ mice (n¼ 3). (B) OPA1, Flag-tag and actin western blot analyses from wild-type adipocytes after
transfection with an siRNA scrambled control (Scramble) or Opa1 siRNA (siOPA1) (top panel, Opa1 western blot) or siOPA1 samples
retransfected with hOPA1-S1 or hOPA1-DS1 (bottom panel, Flag western blot). To the right of each representative western blot, is the
densitometry analysis from three independent experiments, normalized to actin levels. (C) Palmitate oxidation rate in wild-type brown
adipocytes after 72 h of the above transfections. Bars represent mean values±s.e.m. of three independent experiments. *Po0.05; ***Po0.001.
Figure source data can be found in Supplementary data.
Metabolic control by mitochondrial protease OMA1
PM Quiro´s et al
&2012 European Molecular Biology Organization The EMBO Journal 11
In addition to its mitochondrial pro-fusion activity, OPA1
plays an important role in the maintenance of cristae junc-
tions of the organelle, protecting cells from apoptosis by
preventing cytochrome c release and mitochondrial depolar-
ization (Olichon et al, 2003; Cipolat et al, 2006; Frezza et al,
2006). Accordingly, we also examined whether the defects in
L-OPA1 proteolytic processing observed in Oma1-deficient
cells could have an impact on apoptosis in these cells. In
fact, Oma1/ cells display low sensitivity to apoptosis
compared with control cells, thus demonstrating that the
absence of OMA1 metalloprotease has a profound impact
on both pro-fusion and anti-apoptotic activities of OPA1. The
proposed implication of OMA1 in the OPA1-mediated control
of cristae remodelling and cytochrome c release during
apoptosis likely derives from its ability to cleave L-OPA1
isoforms. In fact, these transmembrane isoforms keep in
check the cristae junctions through the formation of stabiliz-
ing oligomeric structures with soluble short isoforms of OPA1
(Cipolat et al, 2006; Frezza et al, 2006). Since Oma1-deficient
cells maintain their L-OPA1 isoforms intact, even under stress
conditions, and still have available some soluble S-OPA1
isoform, the tight structural organization of cristae junctions
is completely preserved. This situation prevents the redis-
tribution and release of cristae-stored cytochrome c and
finally results in apoptosis impairment. Notably, we also
observed a significant decrease of mtDNA levels in
Oma1/ cells, which was not a consequence of any putative
mitochondrial mass decrease between normal and mutant
cells. The recent finding that OPA1 is also linked to mtDNA
stability (Landes et al, 2010) suggests that the OPA1-proces-
sing deficiency found in mitochondria from Oma1/ cells
could contribute to explain why these cells are prone to
mtDNA loss.
Interestingly, despite all these mitochondrial abnormalities
observed in Oma1/ cells, including inhibition of mitochon-
drial fission and loss of mtDNA, mitochondria deficient in
OMA1 metalloprotease do not display marked respiratory
defects, indicating that this enzyme is dispensable for
OXPHOS function. This somewhat paradoxical situation is
not unprecedented, as mitochondria deficient in rhomboid
PARL1 protease do not exhibit primary respiratory defects in
a variety of cell types, although this enzyme is also involved
in OPA1 processing (Cipolat et al, 2006). These observations
reinforce the usefulness of in vivo models to define the
specific functions of proteins, which form part of complex
and redundant regulatory pathways like those involving
proteolytic systems (Lopez-Otin and Bond, 2008; Lopez-
Otin and Hunter, 2010). In fact, over recent years, several
mitochondrial proteases from different catalytic classes,
including the serine protease PARL1 and several ATP-
dependent and -independent metalloproteases, have been
implicated in the constitutive or regulated proteolytic proces-
sing of mammalian OPA1 (Cipolat et al, 2006; Ishihara et al,
2006; Griparic et al, 2007; Song et al, 2007). These studies
were initially based on in vitro experiments involving cell
cultures and pointed to a large degree of overlapping func-
tions between candidate OPA1-processing proteases.
However, the recent introduction of studies based on animal
models of protease deficiency such as those presented herein,
has finally demonstrated the non-redundant in vivo role of
enzymes such as OMA1 in the proteolytic regulation of the
mitochondrial function of the dynamin-related GTPase OPA1.
It is also remarkable that the absence of significant patho-
logical alterations in adult mice deficient in OMA1 facilitated
the identification of the obesity phenotype, which has led us
to propose a new and unexpected role for this mitochondrial
protease in metabolic control. How can we explain that the
deficient OPA1 processing observed in Oma1-null mice leads
to an obesity phenotype? Our data indicate that Oma1
deficiency causes reduced energy expenditure, which agrees
with previous results, indicating that a reduction in energy
expenditure causes obesity in animal models (Lowell et al,
1993; Feldmann et al, 2009). Accordingly, we suggest that the
reduced energy expenditure in Oma1-deficient mice may
account for their increased adipose mass. In addition,
Oma1 deficiency causes a reduced expression of nuclear
genes encoding for mitochondrial proteins and key metabolic
transcription co-activators, and this may be instrumental in
the reduced energy expenditure shown in Oma1-null mice.
Moreover, deregulation in lipid metabolism due to defects in
b-oxidation genes observed in Oma1-deficient mice contri-
butes to the obesity and thermoregulation defects. In this
respect, we can speculate that altered OPA1 processing
induces changes in mitochondrial dynamics, modifying
expression levels of dynamic proteins to compensate or
counteract this deficiency. Thus, under physiological condi-
tions and in the absence of any relevant stressor, the lack of
OMA1 induces changes in mitochondrial dynamics without
seriously affecting any physiological function. In this situa-
tion, Oma1-deficient mice display a modest increase in body
weight, improvement in glucose metabolism, hepatic steato-
sis, decrement in energy expenditure and low body tempera-
ture. However, under stress conditions such as a high-fat diet,
the lack of OMA1 induces obesity, loss of glucose metabolism
improvement and decrease in b-oxidation that induce the
marked increase in the expression of genes of the lipogenic
pathway and manifests as the significant hepatic steatosis
observed in Oma1-deficient mice. Likewise, cold-stress in-
duces impaired thermogenic response diminishing core body
temperature, due to defects in b-oxidation and dysfunction
in mitochondrial dynamics in response to cold-stress.
Interestingly, a recent in vitro study using 3T3-L1 adipocytes
has described a new function for OPA1 as a dual-specificity
A-kinase anchoring protein, which interacts with perilipin
and PKA forming a supramolecular complex involved in the
lipolysis of lipid droplets (Pidoux et al, 2011). We did not
observe any change in perilipin phosphorylation in Oma1-
deficient BAT in comparison to normal tissue (data not
shown), although this does suggests that perilipin functions
normally in Oma1/ BAT and likely does not contribute to
the numerous defects we have described in these mutant
mice, it may function in other tissues, for example white
adipose, a possibility that will require further detailed exam-
ination in the future. Finally, and in relation to the putative
implications of these findings for human metabolic control,
several genome-wide linkage studies have found evidence of
a quantitative trait locus for human obesity phenotypes in the
region harbouring OMA1 (Saar et al, 2003; Choquette et al,
2008). Nevertheless, further epidemiological studies will also
be necessary to clarify the putative relevance of OMA1
mutations or polymorphisms in abnormal weight control
and glucose metabolism in humans.
In summary, the generation and characterization of
Oma1-deficient mice has contributed to clarifying the
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in vivo functional role of this metalloproteinase in mitochon-
drial quality control and metabolic homeostasis (Figure 7).
The first steps in these processes are performed by mitochon-
drial peptidases, which play direct roles in the degradation of
misfolded and damaged proteins or participate in the proteo-
lytic processing of proteins that form part of the mitochon-
drial dynamics machinery. OMA1 belongs to this second
category of mitochondrial proteases due to its ability to target
OPA1. Accordingly, Oma1-deficient cells have marked altera-
tions in mitochondrial dynamics due to the incomplete
processing of L-OPA1. This perturbation of the fusion–fission
equilibrium in Oma1/ cells has clear implications for
metabolic homeostasis and causes a series of energy meta-
bolic derangements, which finally result in abnormal weight
control, hepatic steatosis and defective thermogenesis. The
absence of OMA1 is especially significant under stress con-
ditions, indicating that an intact OMA1-OPA1 system is
essential for developing the appropriate adaptive response
to different metabolic stressors such as high-fat diet or
cold-shock. However, we cannot discard that, despite all
of these metabolic derangements observed, other potential
substrates/interacting proteins for OMA1 may be involved
in this process. The marked transcriptional changes observed
in genes of lipid and glucose metabolic pathways and the
substantial alterations in circulating blood parameters found
in Oma1-mutant mice, are likely part of an exacerbated or
anomalous adaptive response, which finally fails in the
absence of OMA1 and leads to the phenotypes observed in
these mice including obesity and defective thermogenesis.
Hopefully, the identification of OMA1 as a proteolytic enzyme
involved in the regulation of energy metabolism may open
new ways for a better understanding of human obesity, a
major medical problem that is reaching epidemic dimensions
worldwide.
Materials and methods
Generation of Oma1/ mice
We first constructed the targeting vector in pKO scrambler V916
(Lexicon Genetics). A 4.3-kb SalI–NotI fragment from 50-flanking
region, exon 1 and part of intron 1 was used as the 50-homologous
region, whereas a 3.2-kb XhoI–ClaI fragment containing part of
intron 2 and exon 3 was used as the 30-region of homology. The
2.4-kb neo cassette was used as a positive marker and replaced a
2.9-kb fragment containing exon 2 of the Oma1 gene. The
thymidine kinase marker was used as negative selection (Supple-
mentary Figure S1A). The targeting vector was linearized by
digestion with NotI, electroporated into G4 embryonic stem cells,
Figure 7 Schematic model summarizing the functional relevance of OMA1 in mitochondrial dynamics and metabolic homeostasis.
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and selected for homologous recombination with G418 and
ganciclovir. Positive clones were screened by Southern blot after
PvuII digestion of genomic DNA and probed with radiolabelled
30-external probe. A 7.5-kb fragment was detected from wild-type
allele and a 4.3-kb fragment from mutant allele. The targeted ES
cells clones were expanded and subsequently injected into
blastocysts to generate chimeras. Chimeric males were mated with
C57BL/6 female mice and the offspring heterozygous for Oma1
were used to generate homozygous null mice. In all cases, mice
genotypes were determined by PCR analysis of tail DNA.
Animal care
All animal procedures were approved in accordance with the
guidelines of the Committee for Animal Experimentation of the
Universidad de Oviedo. For diet-induced obesity, 4-week-old Oma1-
deficient mice and their wild-type littermates (C57BL/6/129Sv)
were kept in microisolation cages on a 12-h day–night cycle and fed
a high-fat diet containing 42% fat (Harlan TD 88137). Mice were
weighted once a week for all the experiments. After 24 weeks, mice
were sacrificed by cervical dislocation.
Histological analysis
Tissues were fixed in 4% paraformaldehyde in phosphate-buffered
saline (PBS) and stored in 70% ethanol. Fixed tissues were
embedded in paraffin by standard procedures. Blocks were
sectioned (5 mm) and stained with haematoxylin and eosin (H&E).
For adipose tissue evaluation, portions of gonadal and subscapular
fat pads and pieces of skin were processed as described above. The
number of adipocytes and their mean diameter were determined in
3mm tissue sections by computer-assisted image analysis. For each
sample, different sections were analysed and 100 adipocytes were
measured. The area of cells was calculated considering the
maximum and minimum diameter of each adipocyte. For triglycer-
ide detection, liver samples were fixed with 4% formaldehyde and
left overnight at 41C. After that, samples were treated with 15%
sucrose in PBS for 4 h, and then with 30% sucrose solution
overnight, embedded in Tissue-Tek OCT compound (Sakura
Finetechnical Co. Ltd.) and stored at 701C. Finally, samples were
sectioned at 5mm thickness with cryostat (CM3050 S, Leica) and
cryosections were stained with Oil Red O. For BAT droplets
quantification, pictures from BAT sections stained with H&E were
analysed with Image J software.
Blood and plasma parameters
Animals fed on regular and high-fat diet were fasted overnight
and used for measurements of blood and plasma parameters.
Blood glucose was measured with Accu-Chek glucometer (Roche
Diagnostics) using blood from the tail vein. For all the other
measured parameters, blood was extracted directly from heart after
anaesthetizing mice with halothane. Plasma was obtained as
previously described. Briefly, blood was immediately centrifuged
after collection at 3000 g and 41C, and the supernatant was collected
and stored at 801C until analysis. For plasma insulin, leptin and
free fatty-acid measurements, we used Millipore ELISA Kits. All
protocols were performed according to the manufacturer’s instruc-
tions. Levels of hepatic transaminases, cholesterol and triglycerides
were determined in the Servicio de Bioquı´mica, Hospital Universi-
tario Central de Asturias, Oviedo, Spain.
Glucose and insulin tolerance test
Prior to studies, mice were fasted overnight. For IPGTT, mice
received an intraperitoneal injection of glucose (2mg/g body
weight). In IPITT studies, mice received an intraperitoneal injection
of 1U of insulin per kg of body weight. Blood glucose levels were
determined as describe above. Areas under the curve during IPGTT
and IPITT were then calculated by the linear trapezoidal method.
Indirect calorimetry
Energy expenditure and ambulation were assessed using Micro-
Oxymax multiple sensor (Columbus Instruments). Oma1þ /þ and
Oma1/ mice kept on standard rodent chow were housed
individually in Oxymax chambers and kept on a 12:12-h light–dark
cycle. Constant airflow (0.5 l/min) was drawn through each
chamber. After 1 day of acclimation, O2 consumption, CO2
production, RQ, heat and ambulation parameters were recorded
during 72h, using software provided by Columbus Instruments.
RNA preparation
Collected tissue was immediately homogenized in TRI reagent
(Sigma-Aldrich, St Louis, MO, USA) and processed in the same day
through alcohol precipitation according to the manufacturer’s
instructions. RNA pellets were then washed in cold 80% ethanol
and stored at 801C until further use. Following resuspension of
RNA in nuclease-free water (Ambion, Austin, TX, USA), the
samples were quantified and evaluated for purity (260/280nm
ratio) using a NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA), and 100mg of each sample
was further purified using RNeasy spin columns according to the
manufacturer’s instructions (Qiagen, Valencia, CA, USA).
Transcriptional profiling and gene expression analysis
The full transcriptome analysis was conducted using Affymetrix
Mouse Gene 1.0 ST Array according to the protocols recommended
by the manufacturer (Affymetrix, Santa Clara, CA, USA). Total RNA
was isolated as described above from mice tissues maintained
under the same high-fat diet and light/dark cycle conditions. The
RNA integrity was assessed using Agilent 2100 Bioanalyzer (Agilent,
Palo Alto, CA, USA). Labelling and hybridizations were performed
according to the protocols from Affymetrix. Washing and scanning
were performed using Fluidics Station 400 and GeneChip Scanner
(Affymetrix). After scanning, raw data were processed with
RMAExpress (http://RMAExpress.bmbolstad.com), using default
settings. DAVID, Ingenuity and OpenOffice software were used for
data analysis. The DAVID web portal was used to calculate
statistical enrichment of KEGG pathways and Gene Ontology
biological processes for each group (Dennis et al, 2003; Huang da
et al, 2009). The network analyses were generated through the
use of Ingenuity Pathways Analysis (Ingenuitys Systems; http://
www.ingenuity.com).
Real-time quantitative PCR
cDNAwas synthesized using 1–5mg of total RNA, 0.14mM random
hexamer primer, 0.2mM of each deoxynucleoside triphosphate and
Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA).
Quantitative reverse transcription–PCR (qRT–PCR) was carried out
in triplicate for each sample using 20ng of cDNA, TaqMans
Universal PCR master mix (Applied Biosystems, San Francisco, CA,
USA), and 1 ml of the specific TaqMan custom gene expression assay
for the gene of interest (Applied Biosystems). To quantitate gene
expression, PCR was performed at 951C for 10min, followed by 40
cycles at 951C for 15 s, 601C for 30 s and 721C for 30 s using an ABI
Prism 7300 sequence detector system. As an internal control, gene
expression was normalized to the mouse b-actin gene using the
Mouse b-actin Endogenous Control (VICs/MGB Probe, Primer
Limited) TaqMan gene expression assay (Applied Biosystems).
Relative expression of the analysed genes was calculated according
to the manufacturer’s instructions. Briefly, the analysed gene
expression was normalized to b-actin in wild-type or Oma1/
derived samples, using the following formula: the mean value of
2DCTgene (Gene of interest)DCTgene (b-actin) for at least six different wild-
type animals were considered 100% for each analysed gene and the
same values for Oma1/mice tissues were referred to those values
as previously described.
Western blotting
Mice tissues were immediately frozen in liquid nitrogen after
extraction, then homogenized in 50mM Tris buffer, pH 7.4,
containing 150mM NaCl, 1% Triton X-100, 10mM EDTA and
complete protease inhibitor cocktail (Roche Applied Science). Once
homogenized, tissue extracts were centrifuged at 13 000 g and 41C
for 5min, and supernatants were collected. The protein concentra-
tion of the supernatant was evaluated by bicinchoninic acid
technique (BCA protein assay kit; Pierce Biotechnology Inc.). A
protein sample (15mg) was loaded on SDS–polyacrylamide gels.
After electrophoresis, gels were electrotransferred onto PVDF filters,
and the filters were blocked with 5% non-fat dried milk in TBS-T
(TBS with 0.05% Tween-20) and incubated with primary antibodies
following the commercial instructions. After three washes with
TBS-T, filters were incubated with the corresponding secondary
antibody in 1.5% milk in TBS-T, and developed with Immobilon
Western Chemiluminescent HRP substrate (Millipore) in a LAS-
3000 Imaging System (Fujifilm). The antibodies against OPA1 and
DRP1 were from BD Bioscience, and the antibody against MFN2
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was from Abcam. All the other antibodies used in this work were
from Cell Signaling.
Cell culture and microscopy analysis
Primary MEFs were extracted from E13.5 embryos. Briefly, embryos
were sterilized with ethanol, washed with PBS and triturated with
razor blades. Samples were then incubated in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco) overnight at 371C and 5% CO2.
The next day, cultured cells were trypsinized and washed. Finally,
MEFs were incubated at 371C and 5% CO2 and used for the
corresponding experiments. Adult murine fibroblasts (AFs) were
extracted from 12-week-old mice ears. Ears were sterilized with
ethanol, washed with PBS and triturated with razor blades. Samples
were then incubated with 600 ml of 4mg/ml collagenase D (Roche
Applied Science) and 4mg/ml dispase II (Roche Applied Science) in
DMEM (Gibco) for 45min at 371C and 5% CO2. After filtering and
washing, 6ml of DMEM with 10% fetal bovine serum (Invitrogen),
and 1% antimycotic-antibiotic (Invitrogen) were added, and the
mixture was incubated at 371C and 5% CO2. Once extracted, cells
were cultured in DMEM containing 10% fetal bovine serum at 371C
and 5% CO2. Brown preadipocytes were isolated from newborn
mice by collagenase digestion and were differentiated to mature
adipocytes as previously described (Fasshauer et al, 2000).
Immortalized MEFs, AFs and preadipocytes were generated by
SV40 transformation. For fluorescence microscope analyses, mito-
chondrial morphology was examined after transfection of vector
containing mito-DsRed, and images were obtained using a laser-
scanning confocal microscope (TCS-SP2-AOBS; Leica) using HCX
PL APO Ibd BL  63 NA 1.4 objective lens. Images were acquired
with LCS Suite version 2.61 (Leica), and then modified with ImageJ,
using the maxima projection of 0.2mm stacks images after
convolve, median filter and despeckle modification. Brightness/
contrast was adjusted using ImageJ.
Transmission electron microscopy
BAT samples were dissected from control and cold-stress-induced
mice and fixed in 3% glutaraldehyde in 0.1M sodium cacodylate
(pH 7.2) for 1 h at 41C. After three washes in 0.1M Sorensen’s
phosphate buffer, samples were postfixed with 1% osmium
tetroxide for 1 h and rinsed three times in Sorensen’s buffer. Tissues
were dehydrated in graded ethanol and infiltrated in 50% propylene
oxide/50% resin for 1 h, then placed in resin for 1 h, and embedded
in a resin-based mould for polymerization overnight in a 371C oven.
Ultra-thin sections (85 nm) were taken from each sample and
analysed on a Jeol (JEM-1011) transmission electron microscope at
80 kV. Images were modified using ImageJ and Gimp 2.6 software.
Proliferation assays
Growth capacity was determined in six-well test plates in which
6104 cells were plated per well in 2.5ml of DMEM medium and
incubated at 371C for 72 h. Cells were daily counted by using a
Neubauer chamber. Population doubling time was calculated using
the algorithm provided by http://www.doubling-time.com.
Mitochondrial ATP content
Cellular ATP levels were determined using the ATP determination
kit (Molecular probes, Invitrogen) according to the instructions of
the manufacturer. Briefly, MEFs were collected by trypsinization
and lysed using PLB (Promega). The lysates were centrifuged at
12 000 g and 41C for 5min, and supernatants were collected. The
protein concentration of the supernatant was evaluated by
bicinchoninic acid technique (BCA protein assay kit, Pierce
Biotechnology, Rockford, IL, USA). We used 3 mg of lysated material
for ATP determination with a D-luciferin/firefly luciferase reaction
mix, and luminescence was measured in a Luminometer TD20/20
and compared with a freshly prepared ATP standard curve.
Mitochondrial DNA copy number quantification
We quantified mtDNA by real-time PCR using ABI PRISM 7300
Sequence Detector System (Applied Biosystems) and TaqMan
Universal PCR master mix (Applied Biosystems). Total DNA was
used as a template and amplified with specific oligodeoxynucleo-
tides for mt-Co2 and Sdha. We calculated the mtDNA copy number
per cell using Sdha amplification as a reference for nuclear genome
(Moreno-Loshuertos et al, 2006).
Citrate synthase activity
We determined mitochondrial citrate synthase activity in whole
MEFs lysates and tissues homogenates. Briefly, MEFs were collected
by trypsinization, washed twice with PBS and resuspended in buffer
A (0.25M sucrose and 20mMMOPS-KOH, pH 7.4). Then, we added
digitonin to a final concentration of 0.1mg/ml, and cells were kept
on ice for 5min and centrifuged at 5000 g and 41C for 5min. The
pellets were resuspended in buffer B (0.25M sucrose, 1mM EDTA
and 20mM MOPS-KOH, pH 7.4), kept on ice 5min and centrifuged
again at 10 000 g. The final mitochondrial fraction pellets were
resuspended in 10mM of potassium phosphate buffer (pH 7.4) and
samples were freezed-thawed three times in liquid nitrogen before
use. For tissue analysis, homogenates were prepared as described in
palmitate oxidation protocol. Citrate synthase activity was deter-
mined spectrophotometrically at 301C as the reduction rate of
100mM DTNB (5,50-dithio-bis-2-nitrobenzoic acid) at 412 nm
(e¼ 13.8/mM/cm) after the addition of 400mM acetyl-Coenzyme
A and 500mM oxalacetate (Sigma-Aldrich).
Oxygen consumption measurements
Endogenous respiration measurements in intact cells or polarogra-
phy in digitonin-permeabilized cells were performed using a Clark
type oxygen electrode (Hansatech) as previously described
(Hofhaus et al, 1996; Acin-Perez et al, 2003). Briefly, for the O2
consumption determinations in intact cells to measure the
maximum respiration capacity, exponentially growing cells were
collected by trypsinization and centrifugation, and resuspended at
6.5106 cells/ml in 0.75ml of DMEM containing glucose (4.5 g/l),
supplemented with 10% FBS. The cell suspension was transferred
to the electrode’s 1.5ml water-jacketed chamber containing a small
magnetic bar, thermostated at 371C. Recording of oxygen consump-
tion was carried out for 150 s. Then, 65 nmol 2,4-dinitrophenol
(DNP; Sigma) were added to uncouple the respiration and oxygen
consumption was monitored for an additional 150 s to determine
the maximum O2 consumption. For polarographic measurements
of the individual respiratory complexes, cells were collected
by trypsinization and centrifugation, and resuspended at
2–5106 cells/ml in Respiration Buffer (250mM HEPES, pH 7.1;
250mM sucrose, 10mM MgCl2, 1mM ADP and 2mM potassium
phosphate). Cells were permeabilized using 10–20mg digitonin per
106 cells and the oxygen consumption rates were determined using
specific substrates and inhibitors for each of the respiratory
complexes: glutamateþmalate and rotenone for complex I;
succinateþ glycerol-3-phosphate and antimycin A for complex III;
TMPD and KCN for complex IV.
Palmitate oxidation measurement
Oxidation of [1-14C]-palmitic acid by tissue homogenates was
performed as previously described (Hirschey et al, 2010). Briefly,
liver and BAT samples were extracted and homogenized in sucrose/
Tris/EDTA buffer, incubated for 120min in the reaction mixture (pH
8.0) containing [1-14C]-palmitic acid, and measured for acid-soluble
metabolites. Palmitate oxidation rates in primary brown adipocytes
were quantified as described (Antinozzi et al, 1998) and corrected
for total cellular protein content.
Statistical analysis
All experimental data are reported as mean and the error bars
represent the standard error of the mean (s.e.m.). Differences
between mean values were analysed by two-tailed Student’s t-test.
A value of Po0.05 was considered significant. Statistical significant
differences are shown with asterisks.
Accession numbers
The Affymetrics GeneChip data set is publicly available from the
Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/)
with the accession number GSE27525.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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